No Data
H.C. Wainwright Maintains Scholar Rock(SRRK.US) With Buy Rating, Maintains Target Price $30
H.C. Wainwright analyst Andres Y. Maldonado maintains $Scholar Rock(SRRK.US)$ with a buy rating, and maintains the target price at $30.According to TipRanks data, the analyst has a success rate of 48.
Scholar Rock Provides Preclinical Data for Its Investigational Obesity Candidate
Scholar Rock Has Dosed The First Participants In The Phase 2 EMBRAZE Proof-of-concept Trial Of Apitegromab To Preserve Lean Muscle Mass In Individuals Living With Obesity And On Background Therapy Of A GLP-1 Receptor Agonist
The trial will also evaluate the effects of apitegromab on the durability of weight loss upon withdrawal of GLP-1 RA therapy. The results from this trial will inform the development of SRK-439, a nove
Express News | Scholar Rock Holding Corp: First Participants Were Dosed in Phase 2 Embraze Proof-of-Concept Trial
Express News | Scholar Rock Announces New Srk-439 Preclinical Data Showing Significant Lean Mass Preservation and Attenuation of Fat Mass Rebound Following GLP-1 Receptor Agonist Withdrawal
Have Insiders Sold Scholar Rock Holding Shares Recently?
Investors may wish to note that the CFO, COO & Treasurer of Scholar Rock Holding Corporation, Edward Myles, recently netted US$85k from selling stock, receiving an average price of US$8.98. It migh